Description: Kiromic BioPharma, Inc. operates as a biotechnology company. The Company focuses on target discovery and gene editing through artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology. Kiromic BioPharma serves customers in the United States.
Home Page: www.kiromic.com
KRBP Technical Analysis
7707 Fannin
Houston,
TX
77054
United States
Phone:
832 968 4888
Officers
| Name | Title |
|---|---|
| Mr. Pietro Bersani CPA, J.D. | CEO & Director |
| Dr. Scott Dahlbeck M.D., Pharm.D., PharmD | Chief of Staff |
| Mr. Daniel Clark | Chief Financial Officer |
| Dr. Leonardo Mirandola Ph.D. | Chief Scientific Officer |
| Dr. Michael Ryan Ph.D. | Chief Bioinformatics Research Computing Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.106 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-10-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 60 |